It is not known how long children with Haemophilus influenzae serotype b (Hib) vaccine failure retain protective Hib antibody concentrations after infection. The objective of this study was to determine Hib antibody concentrations in children several years after infection and to identify risk factors for low antibody concentrations.
The vaccine was initially given at 2, 3, and 4 months of age, with no booster dose, after clinical trials confirmed that it was well-tolerated and efficacious and produced antibody concentrations consistent with those needed for protection in almost all children [2, 8, 9] . At the same time, a catch-up campaign was initiated over a 12-month period that offered 3 doses of vaccine at monthly intervals to infants aged 4-12 months of age and a single dose to children aged 12-48 months. The incidence of invasive Hib disease decreased dramatically within 2 years across all age groups, probably through a combination of direct and indirect protection (herd immunity) [10] . From 2000 onward, however, the number of cases increased, particularly in children aged !5 years [11, 12] . Reasons for this increase may have included a decrease in herd immunity, decreased natural boosting to sustain antibody concentrations, and interference with the primary immune response as a result of use of the Hib conjugate combination vaccine containing diphtheria, tetanus, and acellular pertussis (DTaP-Hib) [6, 12, 13] . A booster campaign with Hib vaccine that offered 1 dose to all children aged 6 months to 4 years was therefore conducted from May through September 2003. Within 12 months, the campaign resulted in a dramatic reduction in the number of cases in the age groups targeted for the booster, followed by a reduction in the number of cases among older children and adults [12] .
The development of invasive Hib disease after prior receipt of a Hib conjugate vaccine (i.e., Hib vaccine failure) is extremely uncommon [7] but has been reported in other countries with established Hib vaccination programs, including those with routine booster doses in the second year of life [14, 15] . Children with Hib vaccine failure often have underlying medical conditions, and although many children have low concentrations of antibodies against the organism's polysaccharide (polyribosylribitol phosphate [PRP] ) capsule at the time of infection, the majority will mount an adequate immune response to the infection during the convalescent phase [7, 16] . Almost all of the individuals who do not develop this immune response will respond to an additional dose of Hib vaccine [7, 16] , although a recent study demonstrated that the avidity of these antibodies was significantly lower than that in healthy vaccinated control subjects [17] . The objective of this study was to determine Hib antibody concentrations in children several years after Hib infection and to identify risk factors for low antibody concentrations.
PATIENTS AND METHODS
Cohort of patients with Hib vaccine failure. Hib vaccine failure was defined as invasive Hib disease occurring any time after receipt of 3 doses of Hib conjugate vaccine given in the first year of life, 11 week after receipt of 2 doses given in the first year, or 12 weeks after receipt of a single dose given after the first year [4, 7, 16, 18] . Details of recruitment of children with Hib vaccine failure are described elsewhere [19] . In brief, children with Hib vaccine failure in the United Kingdom were identified through national surveillance of H. influenzae infection by the Oxford Vaccine Group and the Health Protection Agency Centre for Infections [11] . General practitioners caring for children with Hib vaccine failure were contacted from January through December 2006 for permission to approach the family and to confirm the child's Hib vaccination status. In accordance with national guidelines, children with Hib vaccine failure also received another dose of Hib vaccine before hospital discharge or had Hib antibody concentrations measured after infection and were revaccinated if antibody concentrations were !1.0 mg/mL [20, 36] . Moreover, children aged 6 months through 4 years on 1 April 2003 (the group most likely to have been vaccinated with DTaP-Hib during infancy) received another dose of Hib vaccine as part of the 2003 Hib booster campaign [12] . The families of children who had died were excluded from the study, as were families that the general practitioner considered to be inappropriate to contact. After a positive response from the general practitioner, the families were invited to participate in the study, which involved completion of a questionnaire and obtainment of a blood sample from the child.
Population control samples. Population control samples were obtained from a recent study on the impact of Hib vaccination on population immunity in children aged !16 years that used 12600 anonymous serum samples from the UK Public Health Laboratory Service Seroepidemiology Unit collection [21] . Serum samples from the period 1990-1991 were considered to represent the period before the introduction of routine Hib vaccination (the unvaccinated cohort). Samples obtained during 2000 represented the period after the introduction of routine Hib vaccination (the vaccinated cohort), when most children would have received the Hib vaccine, although children born before October 1988 would have been too old for the 1992 Hib catch-up campaign.
Assays. Anti-PRP antibody concentrations were measured using standard Hib oligosaccharide-conjugated to human serum albumin enzyme-linked immunosorbent assay (ELISA) [22] at the Centre for Clinical Vaccinology and Tropical Medicine in Oxford (samples from vaccine failure cases) and at the Centre for Applied Microbiology and Research, Health Protection Agency, in Salisbury (population control samples). Hib antibody concentrations were determined by reference to a standard curve, which was generated using known dilutions of a standard anti-PRP reference serum sample (Food and Drug Administration; lot 1983), and assay acceptance criteria were based on performance of internal quality-control serum samples (within 2 standard deviations of previously established mean immunoglobulin (Ig) G concentrations of pooled serum samples from adult volunteers) [17] . Although samples were tested at 2 different laboratories, both sites used standard Hib ELISA methodology, which has been shown to yield reproducible results both within and between laboratories [22, 23] , even when clinical samples are retested after several years [17] . The lower limit of antibody detection for the Hib ELISA was 0.10 mg/mL. Ig concentrations were measured by nephelometry (Beckmann Coulter). Ig deficiency was considered to be present if the concentration was у2 standard deviations below the mean for age [24] .
Data analysis. Data were entered into Microsoft Excel and were analyzed using Stata, version 9.0 (Stata). Continuous data were expressed as mean deviation (if they values ‫ע‬ standard followed a normal distribution) or as median values and interquartile ranges (IQRs) and were compared using the nonparametric Mann-Whitney U test. Categorical variables were expressed as proportions and were compared using the x 2 test. Because data on Hib antibody concentrations were highly skewed, even when log-transformed, median values are reported. The binomial method was used to calculate 95% confidence intervals for the median values. A backward, stepwise multivariable logistic regression model was used to analyze the relationship between the different explanatory variables and low anti-PRP antibody concentrations at follow-up. All parameters in the univariate analysis with a P value !.2 were incorporated into the model. The least statistically significant parameter was then sequentially removed until only those parameters with a P value !.05 remained. Act to process confidential patient information for monitoring efficacy and safety of vaccination programs [25] .
RESULTS
Of the 323 families approached, 260 (80.5%) returned a completed questionnaire and 175 (54.2%) provided a blood sample; 167 (51.7%) of these samples were successfully analyzed, and the serum sample was insufficient for analysis for the remaining 8 cases (Figure 1 ). There was no difference in age at onset of Hib disease, sex, ethnicity, geographic location, presence of underlying conditions, or clinical presentation between children who provided a blood sample and those who declined (data a The 4 children with low anti-PRP antibody concentrations had low immunoglobulin (Ig) M ( ) and low IgA ( ) concenn p 2 n p 2 trations, and the 14 children with anti-PRP antibody concentrations у0.15 mg/mL had low IgA ( ) and IgM ( ) and low n p 9 n p 3 concentrations of all antibody classes ( ). n p 2 not shown). The median age at onset of Hib disease was 2.3 years (IQR, 1.3-3.8 years), the median age at follow-up was 8.4 years (IQR, 6.2-15.4 years), and the median duration of follow-up was 4.1 years (IQR, 3.5-9.7 years). Ninety-six children (57.5%) were boys, 14 (8.4%) had been born prematurely (before 37 weeks of gestation), and 18 (10.8%) had an underlying medical condition, including malignancy (5 cases), Down syndrome (3 cases), congenital abnormalities (3), severe quadriplegic cerebral palsy (2), complex congenital heart disease (2), metabolic disorders (2; congenital adrenal hyperplasia and diabetes insipidus), and primary immunodeficiency (1; common variable immunodeficiency). Children with underlying conditions were more likely to have been born prematurely than were children without underlying conditions (5 [ (Table 1) . Seventeen children (10%) developed long-term sequelae, including severe hearing loss (10 cases), cerebellar damage (2), and hydrocephalus requiring a ventriculo-peritoneal shunt, quadriplegic cerebral palsy, hemiplegia, absence seizures, and cranial nerve palsy (1 each). None of the children had a second episode of Hib.
Hib antibody concentrations. The median anti-PRP antibody concentration for all children was 0.70 mg/mL (IQR, 0.22-5.8 mg/mL; range, !0.10 to 108 mg/mL). It was significantly lower for children with an underlying medical condition than for those without an underlying medical condition (0.13 mg/ mL [IQR, !0.10 to 1.0 mg/mL] vs. 0.81 mg/mL [IQR, !0.10 to 6.0 mg/mL];
), but there was no association with pre-P p .004 maturity, clinical diagnosis, intensive care requirement, or longterm sequelae ( ; data not shown). P 1 .10 Overall, 85 children (56.9%) had antibody concentrations !1.0 mg/mL, and 27 (16.2%) had concentrations !0.15 mg/mL, which are the putative concentrations considered to provide long-term and short-term protection against Hib disease, respectively [26, 27] . Children with underlying conditions (including all 3 children with Down syndrome) were more likely ). In the univariate analysis, anti-PRP P ! .001 antibody concentrations !0.15 mg/mL were associated with an underlying medical condition, younger age at onset of Hib disease, shorter time from Hib disease to follow-up, and premature birth (Table 1) .
Median anti-PRP concentrations in 33 children who had received у1 dose of DTaP-Hib (0.36 mg/mL; IQR, 0.16-1.0 mg/ mL) were lower than those in 134 children who had received combination vaccine containing whole cell pertussis (0.84 mg/ mL; IQR, 0.25-7.1 mg/mL; ), although P p .33 the difference was not statistically significant, possibly because of small numbers. Median anti-PRP concentrations in children with Ig deficiency (0.44 mg/mL; IQR, 0.18-1.9 mg/mL) were lower than those in children with normal Ig concentrations (0.80 mg/mL; IQR, 0.24-5.9 mg/mL), but the difference was not statistically significant ( ). There was also no association P p .30 between Hib antibody concentrations and breastfeeding (any duration), nursery attendance, parental smoking, parental employment status, ownership of a house and/or car, or number of siblings (data not shown). In a logistic regression model (Table 2) , anti-PRP antibody concentrations !0.15 mg/mL were associated with an underlying medical condition, Hib disease before 18 months of age, and a shorter time from Hib disease to follow-up (15% reduction per year of follow-up in the risk of having antibody concentrations !0.15 mg/mL).
Comparison with population control cohorts. Among children aged !5 years, median antibody concentrations were lower in children with vaccine failure than in both unvaccinated and vaccinated cohorts, albeit with wide confidence intervals (Figure 2) . The group with vaccine failure also included a high proportion of children (41.7%) with antibody concentrations !0.15 mg/mL; the proportion was equivalent to that of unvaccinated children (38.3%) but higher than that of vaccinated children (28.9%) of similar age (Figure 3) .
Among children aged 8-11 years, median anti-PRP concen- trations in children with vaccine failure were 3-fold higher than those in both the unvaccinated and the vaccinated cohorts ( Figure 2 ), with only 6.0% having antibody concentrations !0.15 mg/mL, compared with 13.5% and 18.0%, respectively ( Figure 3 ). The group of children with vaccine failure who were aged 8-11 years also had the highest proportion of children with very high antibody concentrations (110 mg/mL) ( Figure  3 ). When compared with other age groups, these children had developed invasive Hib disease when they were older (Table 3) .
The median antibody concentration in children with vaccine failure who were aged 12-15 years (0.64 mg/mL) was significantly lower than that in the unvaccinated (1.45 mg/mL) and vaccinated (1.19 mg/mL) cohorts, although more than onequarter (26.2%) of children with vaccine failure had very high antibody concentrations (110 mg/mL), which was more than twice the proportion of children in the unvaccinated (12.8%) and vaccinated (12.1%) cohorts.
DISCUSSION
We report, to our knowledge, the largest and longest followup study of children with Hib conjugate vaccine failure. We believe that our study participants are representative of the population with Hib vaccine failure, because the geographic, ethnic, demographic, and clinical features of children who provided a blood sample were similar to those who declined. The finding that more than one-half of the children had antibody concentrations !1.0 mg/mL suggests that, perhaps, children with Hib vaccine failure are inherently unable to maintain long-term antibody-based immunity against Hib. Low antibody concentrations were associated with underlying medical conditions, young age at disease onset, and a shorter time from Hib disease to follow-up (Table 2) . Underlying medical conditions included a mixed group that are known to be associated with recurrent and often severe infections and that involve reduced vaccine responses [28] [29] [30] [31] . Of interest, although 20% of children with Hib vaccine failure had received the DTaP-Hib vaccine, which is associated with reduced Hib immunogenicity [13, [32] [33] [34] [35] , they were not more likely to have Hib antibody concentrations !0.15 mg/mL at follow-up (Table 1) . Possible reasons for a lack of association include natural boosting of immunity after invasive Hib disease [16] or receipt of another dose of Hib vaccine after Hib disease in accordance with national UK guidelines [20, 36] or through the 2003 Hib booster campaign [12] . To support this, a recent study reported that children who received a booster dose of Hib vaccine at 2-4 years of age developed similar Hib antibody concentrations after vaccination, irrespective of the type of Hib combination vaccine received during infancy [35] .
Young age at disease onset was also independently associated with an increased risk of low antibody concentrations at followup; almost one-third of children (14 [29%] of 49) who developed Hib infection at !18 months of age had antibody concentrations !0.15 mg/mL at follow-up. Young age at Hib disease onset in unvaccinated children has also been associated with low convalescent anti-PRP concentrations after Hib infection [16] . This can be explained by the inability of young children to develop natural antibodies to bacterial capsular polysaccharide [37, 38] , as demonstrated by the lack of protection afforded by a plain Hib polysaccharide vaccine in children aged !18 months [39] .
The association of low antibody concentrations with a shorter time from Hib disease to follow-up was initially surprising, because antibody concentrations are expected to decrease after infection or vaccination [6, 7, 40] . In our study, 20 (74%) of 27 children with antibody concentrations !0.15 mg/mL had developed Hib disease most recently (2001) (2002) (2003) (2004) (2005) . A recent UK study of children aged 3-5 years who were vaccinated during infancy reported higher anti-PRP levels in those vaccinated during 1991 than in those vaccinated during subsequent years (1992-2000) [41] . Another UK study involving healthy adults reported a decrease in anti-PRP antibody concentrations after the introduction of Hib vaccine [42] . In both studies, the authors proposed that their findings reflect fewer opportunities for natural boosting of immunity after Hib vaccine introduction [41, 42] . It is likely that this mechanism is also relevant to Hib vaccine failure cases. Compared with rates during the prevaccine era, Hib carriage rates in preschool-aged children are currently very low [35, 43, 44] . In contrast, school children aged 6-16 years currently have the highest Hib carriage rates (4.2% of 855 children) [45] . A higher carriage rate may explain the higher anti-PRP antibody concentrations in schoolaged children in our cohort with Hib vaccine failure. When compared with age-related population control subjects, children aged 2-4 years had the lowest antibody concentrations. Particularly concerning is the finding that 140% of children with Hib vaccine failure in this age group were unable to sustain adequate anti-PRP antibody concentrations to provide even short-term protection. This observation is supported by a recent UK study that reported that 23% and 73% of 176 healthy vaccinated children who were aged 2-4 years in 2003 had anti-PRP concentrations !0.15 and !1.0 mg/mL, respectively; however, receipt of DTaP-Hib vaccine during infancy was associated with subsequent lower antibody concentrations in that study [35] .
On the other hand, children with Hib vaccine failure who were aged 8-11 years had the highest anti-PRP antibody concentrations, although the confidence intervals overlapped widely. Almost all children in this age group had been vaccinated during infancy; they would have been too young for the 1992 catch-up campaign and too old for the 2003 booster campaign. They were also born at a time when the incidence of Hib disease was at its lowest; thus, there was a reduced number of opportunities for natural boosting. Therefore, because of increasing circulation of Hib after 1999, this group of children would have been particularly susceptible. The high antibody concentration at follow-up was most likely a consequence of the development of invasive Hib disease at an older age (median age, 4.2 years). Of interest, children in this age group had the highest proportion of clinical presentation with epiglottitis (Table 3 )-a phenomenon also seen in the prevaccine era [5, 46] . In our previous study [16] , children with Hib vaccine failure who developed epiglottitis had the highest convalescent anti-PRP levels, again likely related to their older age. This age group also currently has the highest Hib carriage rates, which may lead to increased opportunities for natural boosting of immunity against Hib disease.
In conclusion, children with clinical Hib vaccine failure may be at risk of further episodes of invasive Hib disease. In our study, at a median of 4 years after their original infection, 57% had antibody concentrations below those considered to confer long-term protection against invasive disease, and 16% had concentrations below those considered to confer short-term protection. In particular, 140% of children aged !5 years at follow-up had anti-PRP concentrations !0.15 mg/mL. It is likely that recent booster campaigns [47] and the introduction of a routine booster dose in the second year of life [12] will further reduce Hib carriage in young children and, therefore, reduce opportunities for natural boosting of immunity-a phenomenon already described in adults. Therefore, survivors of Hib vaccine failure might benefit from an additional dose of the Hib conjugate vaccine several years after infection to provide long-term immunity against Hib disease. This is worthy of further study.
